Fuan Pharmaceutical (Group) Co., Ltd. (SZSE: 300194)
Health Care · Pharmaceuticals · CN
CN¥3.93
-1.75% today · -19.1% 1Y
Fuan Pharmaceutical (Group) Co., Ltd. (SZSE: 300194) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $695.52M and employs 2,988 people.
Over the last twelve months the share price has lost 19.1%, trading between 3.24 and 5.00.
Tweenvest scores Fuan Pharmaceutical (Group) Co., Ltd. across four factors: quality 73/100, value 19/100, growth 9/100, dividend 24/100. Its strongest factor is quality.
300194 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $695.52M
- Revenue (TTM)
- $243.30M
- P/E
- 79.41
- EPS
- 0.05
- Dividend yield
- 1.78%
- Beta (5Y)
- 0.24
- 52-week high
- CN¥5.00
- 52-week low
- CN¥3.24
- Avg volume (3M)
- —
- Shares outstanding
- 1.19B
- Employees
- 2,988
- Next earnings
- —
About Fuan Pharmaceutical (Group) Co., Ltd.
Fuan Pharmaceutical (Group) Co., Ltd. is a comprehensive pharmaceutical enterprise that, along with its subsidiaries, undertakes the research, development, manufacturing, and commercialization of pharmaceutical products across the People's Republic of China. Its product portfolio spans intermediate compounds, active pharmaceutical ingredients (APIs), and finished drug formulations. These formulations cater to a range of therapeutic categories, including anti-infective agents, cardiovascular medications, digestive system remedies, and various other medical products. The group was founded in 2004 and is headquartered in Chongqing, China. It adopted its current name, Fuan Pharmaceutical (Group) Co., Ltd., in August 2013, having previously been known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd.
- ISIN
- CNE1000011G4
- Founded
- 2004
- Listed since
- Mar 22, 2011
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.